KEGG enrichment analysis revealed an enrichment of the NAFLD pathway, suggesting that SLXG may potentially treat nonalcoholic steatohepatitis (NASH) by regulating the expression of genes such as CXCL8, AKT1, SREBF1, IL6, PPARA, and ADIPOQ (Fig. 3B). This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatohepatitis.